Word

CAPSIDA BIOTHERAPEUTICS

Status

Pending

Status Code

731

Status Date

Monday, March 4, 2024

Serial Number

90046614

Mark Type

4000

Filing Date

Friday, July 10, 2020

Published for Opposition

Tuesday, February 7, 2023

Trademark Owner History

CAPSIDA BIOTHERAPEUTICS, INC. - Owner At Publication
Capsida, Inc. - Original Applicant

Classifications

40 Biomanufacturing, namely, manufacturing of pharmaceuticals using biological organisms in the manufacturing process to order and/or specification of others; providing technical information in the field of pharmaceutical manufacturing; custom manufacture of pharmaceuticals; manufacture of nano scale material to the order and specification of others for use in the manufacture of other goods; manufacturing of pharmaceutical preparations for use in gene therapy to the order and specification of others; manufacturing of pharmaceutical preparations for use in gene delivery technology to the order and specification of others; manufacturing of pharmaceutical preparations for use in the treatment of gene therapy treatable diseases to the order and specification of others; manufacturing of pharmaceutical preparations for the treatment of disorders of the central nervous system to the order and specification of others; manufacturing of pharmaceutical preparations for the treatment of cancer to the order and specification of others; manufacture of pharmaceutical preparations that facilitate administration of other pharmaceutical preparations into the brain for enhanced treatment of disorders of the central nervous system and cancer to the order and specification of others; custom manufacturing of biochemical reagents, namely, synthesis for others of clinical medical reagents for use in gene therapy

5 Pharmaceutical preparations for use in gene therapy; pharmaceutical preparations for use in gene delivery technology for use in the treatment of autoimmune, cancer, cardiovascular, central nervous system, diabetic, dermatological, endocrine, fungal, gastrointestinal, hematologic, hepatological, immunological, infectious, inflammatory, liver, menopausal, metabolic, musculoskeletal, neurological, ophthalmologic, orthopedic, pain, peripheral nervous system, psychiatric, respiratory, renal, urogenital, urological, and viral diseases and disorders; pharmaceutical preparations for use in the treatment of gene therapy treatable diseases for use in the treatment of autoimmune, cancer, cardiovascular, central nervous system, diabetic, dermatological, endocrine, fungal, gastrointestinal, hematologic, hepatological, immunological, infectious, inflammatory, liver, menopausal, metabolic, musculoskeletal, neurological, ophthalmologic, orthopedic, pain, peripheral nervous system, psychiatric, respiratory, renal, urogenital, urological, and viral diseases and disorders; gene therapy and prophylaxis products, namely, gene transfer, regulation, modulation and delivery pharmaceutical preparations for the treatment of genetic diseases and disorders; pharmaceutical preparations for the treatment of disorders of the central nervous system; pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations that facilitate administration of other pharmaceutical preparations into the brain for enhanced treatment of disorders of the central nervous system and cancer, in the nature of drug delivery agents consisting of viral capsids that facilitate the delivery of the preparations; pre-filled syringes and vials containing pharmaceutical preparations for the treatment of autoimmune, cancer, cardiovascular, central nervous system, diabetic, dermatological, endocrine, fungal, gastrointestinal, hematologic, hepatological, immunological, infectious, inflammatory, liver, menopausal, metabolic, musculoskeletal, neurological, ophthalmologic, orthopedic, pain, peripheral nervous system, psychiatric, respiratory, renal, urogenital, urological, and viral diseases and disorders and complications associated therewith

1 Chemical and biochemical products for use in gene delivery technology, namely, nucleic acids, including coding and non-coding deoxyribonucleic acids, ribonucleic acids, plasmids, vectors, promotors, enhancers and other regulatory sequences; Chemical and biochemical products for use in gene delivery technology namely, nucleic acids, including coding and non-coding deoxyribonucleic acids, ribonucleic acids, plasmids, vectors, promotors, enhancers and other regulatory sequences for development of therapeutics and the treatment of autoimmune, cancer, cardiovascular, central nervous system, diabetic, dermatological, endocrine, fungal, gastrointestinal, hematologic, hepatological, immunological, infectious, inflammatory, liver, menopausal, metabolic, musculoskeletal, neurological, ophthalmologic, orthopedic, pain, peripheral nervous system, psychiatric, respiratory, renal, urogenital, urological, and viral diseases and disorders

44 Medical treatment of genetic diseases and disorders through use of gene therapy; Medical services, in the nature of gene therapy, in the field of autoimmune, cancer, cardiovascular, central nervous system, diabetic, dermatological, endocrine, fungal, gastrointestinal, hematologic, hepatological, immunological, inflammatory, liver, menopausal, metabolic, musculoskeletal, neurological, ophthalmologic, orthopedic, pain, peripheral nervous system, psychiatric, respiratory, renal, urogenital, and urological, diseases and disorders; Providing patient support services relating to the treatment of medical disorders, namely, providing online medical information in the field of pharmaceutical preparations for treatment of various diseases and providing medical consultancy and advisory services, in the field of gene therapy, via a global computer network; Providing health and medical information about medical disorders, namely information pertaining to gene therapy; Information services, namely, providing medical information pertaining to gene therapy to patients; Providing patient support services relating to cancer and cancer treatment in the nature of an internet-based database of patient medical information where patients can inquire about medical issues and procedures from other patients and can relay information about their medical experiences for support and community; Providing information services, namely, providing medical care consultancy and advisory services pertaining to gene therapy via a global computer network in the field of autoimmune, cancer, cardiovascular, central nervous system, diabetic, dermatological, endocrine, fungal, gastrointestinal, hematologic, hepatological, immunological, inflammatory, liver, menopausal, metabolic, musculoskeletal, neurological, ophthalmologic, orthopedic, pain, peripheral nervous system, psychiatric, respiratory, renal, urogenital, and urological, diseases and disorders; Providing medical information services relating to treatment of medical disorders, namely, providing medical information pertaining to gene therapy to patients and families of patients in the field of administering medication, and patient medical information where patients can inquire about medical issues and procedures pertaining to gene therapy from medical personnel; None of the foregoing related to the fields of disease infection control, disease management, or disease risk

42 Pharmaceutical research and development in the field of gene therapy; consulting services in the fields of biotechnology, pharmaceutical research and development and genetic science; custom design and development of biochemical reagents, namely for use in the synthesis for others of clinical medical reagents for use in gene therapy; development of pharmaceutical preparations for use in gene therapy and gene delivery technology; development of products being genetic therapies; scientific research in the field of genetic engineering, biotechnology research services, and research and development of new products in the field of gene therapeutics and research tools; research and development in the biotechnology field; scientific and medical research and development in the field of autoimmune, cancer, cardiovascular, central nervous system, diabetic, dermatological, endocrine, fungal, gastrointestinal, hematologic, hepatological, immunological, infectious, inflammatory, liver, menopausal, metabolic, musculoskeletal, neurological, ophthalmologic, orthopedic, pain, peripheral nervous system, psychiatric, respiratory, renal, urogenital, urological, and viral diseases and disorders and complications associated therewith; scientific research and product development services for others in the pharmaceutical, biotechnology, medical and agriculture fields; testing, inspection, research, or development of pharmaceutical preparations for gene therapy and gene delivery technology; biomedical research and development, scientific research and development, pharmaceutical research and development and product development services in the fields of genome editing, gene editing, genome engineering, gene modulation, genetic diseases, gene therapy, and cell therapy; product development in the fields of genetic therapies, gene delivery technologies, and effectors to regulate, modulate, and characterize disease states; conducting clinical trials for others in the field of gene therapy design and delivery; biomedical research in the field of gene therapy design and delivery; gene therapy design and product delivery development of biochemical assays; biomedical research and development, scientific research and development, pharmaceutical research and development and product development in the fields of autoimmune, cancer, cardiovascular, central nervous system, diabetic, dermatological, endocrine, fungal, gastrointestinal, hematologic, hepatological, immunological, infectious, inflammatory, liver, menopausal, metabolic, musculoskeletal, neurological, ophthalmologic, orthopedic, pain, peripheral nervous system, psychiatric, respiratory, renal, urogenital, urological, and viral diseases and disorders; medical services, namely, scientific research in the fields of genetic engineering and gene therapy services; medical services, namely, scientific research in the nature of gene therapy design and delivery services in the field of genetic diseases and disorders

CAPSIDA BIO THERAPEUTICS
"BIOTHERAPEUTICS"

Trademark Events

Mar 5, 2024

Notice Of Approval Of Extension Request E-Mailed

Mar 4, 2024

Sou Extension 2 Granted

Mar 4, 2024

Sou Extension 2 Filed

Mar 4, 2024

Sou Teas Extension Received

Sep 29, 2023

Notice Of Approval Of Extension Request E-Mailed

Sep 27, 2023

Sou Extension 1 Granted

Sep 27, 2023

Sou Extension 1 Filed

Sep 27, 2023

Sou Teas Extension Received

Apr 4, 2023

Noa E-Mailed - Sou Required From Applicant

Feb 7, 2023

Official Gazette Publication Confirmation E-Mailed

Feb 7, 2023

Published For Opposition

Jan 18, 2023

Notification Of Notice Of Publication E-Mailed

Jan 5, 2023

Approved For Pub - Principal Register

Dec 21, 2022

Teas/Email Correspondence Entered

Dec 21, 2022

Correspondence Received In Law Office

Dec 21, 2022

Teas Response To Office Action Received

Jun 23, 2022

Notification Of Non-Final Action E-Mailed

Jun 23, 2022

Non-Final Action E-Mailed

Jun 23, 2022

Non-Final Action Written

Jun 21, 2022

Suspension Checked - To Attorney For Action

Mar 16, 2022

Applicant/Correspondence Changes (Non-Responsive) Entered

Mar 16, 2022

Teas Change Of Correspondence Received

Mar 16, 2022

Teas Change Of Owner Address Received

Dec 1, 2021

Report Completed Suspension Check Case Still Suspended

Jun 1, 2021

Notification Of Letter Of Suspension E-Mailed

Jun 1, 2021

Letter Of Suspension E-Mailed

Jun 1, 2021

Suspension Letter Written

Jun 1, 2021

Examiner's Amendment Entered

Jun 1, 2021

Notification Of Examiners Amendment E-Mailed

Jun 1, 2021

Examiners Amendment E-Mailed

Jun 1, 2021

Examiners Amendment -Written

May 28, 2021

Teas/Email Correspondence Entered

May 27, 2021

Correspondence Received In Law Office

May 27, 2021

Teas Response To Office Action Received

Dec 4, 2020

Notification Of Non-Final Action E-Mailed

Dec 4, 2020

Non-Final Action E-Mailed

Dec 4, 2020

Non-Final Action Written

Nov 4, 2020

Automatic Update Of Assignment Of Ownership

Oct 24, 2020

Notification Of Non-Final Action E-Mailed

Oct 24, 2020

Non-Final Action E-Mailed

Oct 24, 2020

Non-Final Action Written

Oct 21, 2020

Assigned To Examiner

Aug 6, 2020

New Application Office Supplied Data Entered

Jul 14, 2020

New Application Entered